Top stories in cardiology: Weight gain increases atrial fibrillation risk, FDA approves gadobutrol injections for cardiac MRIs

Among the top stories in cardiology last week were a study that suggested excessive weight gain may be associated with risk for atrial fibrillation and the FDA approving gadobutrol injections in cardiac MRIs for patients with suspected coronary artery disease.

Other highlights included a study that found a digital stethoscope with artificial intelligence helped detect aortic stenosis and two presentations from the American Society for Preventive Cardiology Congress that determined a community-based wellness program integrating the use of a mobile app improved the CV health of black adults and that assessing sex-specific CVD risk factors for women can personalize management and treatment.

Weight gain confers raised odds of atrial fibrillation

Excessive weight gain may be associated with risk for atrial fibrillation, according to findings published in Heart. Read more.

FDA approves gadobutrol injections for use in cardiac MRIs

Bayer announced it has received approval from the FDA for its gadobutrol injection for use in cardiac MRIs to gauge myocardial perfusion and late gadolinium enhancement in adult patients with suspected coronary artery disease. Read more.

Digital stethoscope with artificial intelligence may detect aortic stenosis

Screening for significant aortic stenosis was fast and effective through the assessment of phonocardiograms by a digital stethoscope and machine learning, according to study results. Read more.

Community-based mobile intervention improves CV health in black adults

SAN ANTONIO — A community-based wellness program that integrates the use of a mobile app improved the CV health of black adults, according to research presented at the American Society for Preventive Cardiology Congress on CVD Prevention. Read more.

Women and CVD: Assessing sex-specific risk factors can personalize management, treatment

SAN ANTONIO — Martha Gulati, MD, MS, FACC, FAHA, emphasized the importance of considering sex-specific risk factors for CVD, especially when assessing women who may not present with the same CV symptoms as men. Read more.